Literature DB >> 9035298

Effect of gene therapy with the herpes simplex virus-thymidine kinase gene on hepatic metastasis in murine colon cancer.

S Hayashi1, N Emi, I Yokoyama, K Uchida, H Takagi.   

Abstract

Hepatic metastasis of colon cancer is an important prognostic factor for survival. In this study, we examined the effect of gene therapy using the herpes simplex virus-thymidine kinase (HS-tk) gene with short-course ganciclovir (GCV) treatment for multiple hepatic metastases of murine colon cancer. Colon26 cells transfected with the HS-tk gene were found to be sensitive to GCV in a concentration-dependent way. On the other hand, induction of the HS-tk gene in the cells had no influence on cell growth in vitro. However, multiple hepatic metastases of Colon26 cells transfected with HS-tk gene were significantly suppressed by the GCV treatment. These results thus suggest that HS-tk gene therapy is useful for the treatment of hepatic metastasis in colon cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9035298     DOI: 10.1007/bf01366937

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  22 in total

1.  A versatile and potentially general approach to the targeting of specific cell types by retroviruses: application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses.

Authors:  P Roux; P Jeanteur; M Piechaczyk
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

Review 2.  Human gene therapy.

Authors:  W F Anderson
Journal:  Science       Date:  1992-05-08       Impact factor: 47.728

3.  Retroviral-mediated gene transfer into hepatocytes in vivo.

Authors:  N Ferry; O Duplessis; D Houssin; O Danos; J M Heard
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

4.  Inhibitory effect of double transfection to xenoendothelial cells using both decay accelerating factor and homologous restriction factor 20 genes on complement dependent cytolysis.

Authors:  S Hayashi; N Emi; K Isobe; I Yokoyama; H Okada; H Takagi
Journal:  J Surg Res       Date:  1996-02-15       Impact factor: 2.192

5.  Repeat hepatic resections for colorectal metastases.

Authors:  K D Griffith; P H Sugarbaker; A E Chang
Journal:  Surgery       Date:  1990-01       Impact factor: 3.982

6.  Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history.

Authors:  J Scheele; R Stangl; A Altendorf-Hofmann
Journal:  Br J Surg       Date:  1990-11       Impact factor: 6.939

7.  The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.

Authors:  S M Freeman; C N Abboud; K A Whartenby; C H Packman; D S Koeplin; F L Moolten; G N Abraham
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701

8.  Multiple transduction as a means of preserving ganciclovir chemosensitivity in sarcoma cells carrying retrovirally transduced herpes thymidine kinase genes.

Authors:  F S Moolten; J M Wells; P J Mroz
Journal:  Cancer Lett       Date:  1992-07-10       Impact factor: 8.679

9.  Adenovirus-mediated in vivo gene transfer and expression in normal rat liver.

Authors:  H A Jaffe; C Danel; G Longenecker; M Metzger; Y Setoguchi; M A Rosenfeld; T W Gant; S S Thorgeirsson; L D Stratford-Perricaudet; M Perricaudet
Journal:  Nat Genet       Date:  1992-08       Impact factor: 38.330

10.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors.

Authors:  K W Culver; Z Ram; S Wallbridge; H Ishii; E H Oldfield; R M Blaese
Journal:  Science       Date:  1992-06-12       Impact factor: 47.728

View more
  1 in total

Review 1.  Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancies.

Authors:  V Schmitz; C Qian; J Ruiz; B Sangro; I Melero; G Mazzolini; I Narvaiza; J Prieto
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.